Okay here is what we did have, I've marked out the milestones we made. I'm putting these all in one post, including new ones, and will go back and sort everything by date.



CMO: $500M product for 2020 with delayed payment
TNBC FTD Approval
Monotherapy Pivotal Phase 3 Trial IND Submission




Remaining (just copied over)

TNBC Phase 2 Trial: First Patient Injected

Non-dilutive financing licensing/partnerships announcements
Multiple offers received with significant upfront and milestone payments
Prostate Test Licensing

TNBC ODD Approval

TNBC Preliminary CTC numbers/trial data

GvHD Phase 2 Trial: First Patient Injected

Animal Preclinical Trials Preliminary Data: Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer

Colon Cancer Phase 2 Trial IND Submission
Monotherapy: IncellDx Dose/CCR5 Analysis Results
Monotherapy Pivotal Phase 3 Trial IND Submission

100 patient safety data on 700 mg complete for BLA
No Serious Adverse Events in over 740 patients to date

July-September
BLA Complete Submission

2019
Prostate Cancer Test 510(k) filing
GvHD Phase 2 Trial Interim Results
Colon Cancer ODD Approval
Prognostic Prostate Cancer Test Licensing
Multiple Sclerosis Phase 2 Trial IND Submission
NASH, Rheumatoid Arthritis, Lupus Animal Studies

Milestones times for last presentation.


My added ones, any more?

Mono pivotal trial approval

Cash fund for 1 year (no more dilutive financing)

Stopping Conversions on Note (by paying it off or having cash for monthly payments)

FDA response to use 525mg safety data with Combo

Results from NASH mice study.